US2018362506A1PendingUtilityA1

Indole compounds and pharmaceutical use thereof

Assignee: JAPAN TOBACCO INCPriority: Nov 25, 2009Filed: Jan 12, 2018Published: Dec 20, 2018
Est. expiryNov 25, 2029(~3.3 yrs left)· nominal 20-yr term from priority
C07D 413/14C07D 471/04C07D 401/14C07D 417/14C07D 405/14C07D 403/14C07D 403/04A61K 31/404A61K 31/416A61K 31/5377
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as described in the specification.

Claims

exact text as granted — not AI-modified
1 .- 26 . (canceled) 
     
     
         27 . A process for producing a compound of formula [I] 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof comprising
 contacting a compound of formula [1] 
 
       
       
         
           
           
               
               
           
         
         with a compound of formula [2] 
       
       
         
           
           
               
               
           
         
         to form a compound of formula [3] 
       
       
         
           
           
               
               
           
         
          and
 converting the compound of formula [3] to the compound of formula [I], 
 
         wherein 
         R 1  is
 (1) a hydrogen atom, 
 (2) a hydroxy group, or 
 (3) a C 1-6  alkoxy group optionally substituted by C 6-10  aryl group(s); 
 
         R 2  and R 3  are the same or different and each is
 (1) a hydrogen atom, or 
 (2) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group; 
 
 
         R 4  is a group selected from 
       
       
         
           
           
               
               
           
         
          which is bonded to the 5-position or the 6-position of the indole ring,
 wherein 
 R 5  is
 (1) a hydrogen atom, or 
 (2) a C 1-6  alkyl group, and 
 
 R 6  is
 (1) a hydrogen atom, 
 (2) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, 
 (c) a carboxy group, 
 (d) a C 1-6  alkoxy-carbonyl group, 
 (e) a C 6-10  aryl group, 
 (f) a C 6-10  aryloxy group, 
 (g) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 (h) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), and 
 (i) a 5- or 6-membered saturated heterocyclic group, 
 
 (3) a C 1-6  alkoxy group, 
 (4) a C 6-10  aryl group, or 
 (5) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, or 
 
 
 R 5  and R 6  form, together with the nitrogen atom they are bonded to, a 5- or 6-membered cyclic amine, wherein said cyclic amine is optionally condensed with a 5- or 6-membered unsaturated heterocycle, that is optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group, 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 1-6  alkoxy-carbonyl group; 
 
 R 7  is
 (1) a hydrogen atom, or 
 (2) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, and 
 (c) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 
 
 R 8  is
 (1) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group optionally substituted by C 6-10 aryl group(s), 
 (c) a C 3-6  cycloalkyl group optionally substituted by C 1-6  alkoxy group(s), 
 (d) a C 6-10  aryl group, 
 (e) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by oxo group(s), 
 (f) a 5- to 8-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from 
  (i) a hydroxy group, 
  (ii) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy group, and 
  (iv) an oxo group, 
 (g) a C 3-6  cycloalkyloxy group, 
 (h) a C 6-10  aryloxy group, 
 (i) a 5- or 6-membered unsaturated heterocyclyloxy group, 
 (j) a 5- or 6-membered saturated heterocyclyloxy group, and 
 (k) an amino group optionally mono- or di-substituted by substituents selected from 
  (i) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a carboxy group and a carboxy-C 1-6  alkoxy group, 
  (ii) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy-carbonyl group optionally substituted by C 6-10  aryl group(s), and 
  (iv) a C 3-6  cycloalkyl-carbonyl group optionally substituted by C 1-6  alkoxy group(s), 
 
 (2) a C 1-6  alkoxy group optionally substituted by C 6-10  aryl group(s), 
 (3) a C 3-6  cycloalkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, 
 
 (4) a C 6-10  aryl group optionally substituted by C 1-6  alkyl group(s) optionally substituted by 1 to 3 halogen atoms, 
 (5) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s) optionally substituted by C 6-10  aryl group(s), 
 (6) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), 
 (7) a 5- or 6-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a C 1-6  alkyl group, 
 (b) a C 1-6  alkyl-carbonyl group, and 
 (c) an oxo group, 
 
 (8) a C 3-6  cycloalkyloxy group, or 
 (9) a C 6-10 aryl-carbonyl group, or 
 
 R 7  and R 8  form, together with the nitrogen atom and carbon atom they are bonded to, a 5- or 6-membered cyclic amine substituted by an oxo group and optionally further substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group optionally substituted by hydroxy group(s), 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 3-6  cycloalkyl group; and 
 
 
         R 9  and R 10  are the same or different and each is an amino-protecting group selected from the group consisting of a tert-butoxycarbonyl group, an ethoxycarbonyl group, a trityl group, a tetrahydropyranyl group, a methoxymethyl group, a 2-(trimethylsilyl)ethoxymethyl group, and a p-toluenesulfonyl group. 
       
     
     
         28 . A compound of formula [1] 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is
 (1) a hydrogen atom, 
 (2) a hydroxy group, or 
 (3) a C 1-6  alkoxy group optionally substituted by C 6-10 aryl group(s); 
 
         R 2  and R 3  are the same or different and each is
 a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group; and 
 
 
         R 9  is an amino-protecting group selected from the group consisting of a tert-butoxycarbonyl group, an ethoxycarbonyl group, a trityl group, a tetrahydropyranyl group, a methoxymethyl group, a 2-(trimethylsilyl)ethoxymethyl group, and a p-toluenesulfonyl group. 
       
     
     
         29 . A compound of formula [2] 
       
         
           
           
               
               
           
         
         wherein 
         R 4  is a group selected from 
       
       
         
           
           
               
               
           
         
          which is bonded to the 5-position or the 6-position of the indole ring,
 wherein 
 R 5  is
 (1) a hydrogen atom, or 
 (2) a C 1-6  alkyl group, and 
 
 R 6  is
 (1) a hydrogen atom, 
 (2) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, 
 (c) a carboxy group, 
 (d) a C 1-6  alkoxy-carbonyl group, 
 (e) a C 6-10  aryl group, 
 (f) a C 6-10  aryloxy group, 
 (g) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 (h) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), and 
 (i) a 5- or 6-membered saturated heterocyclic group, 
 
 (3) a C 1-6  alkoxy group, 
 (4) a C 6-10  aryl group, or 
 (5) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, or 
 
 
 R 5  and R 6  form, together with the nitrogen atom they are bonded to, a 5- or 6-membered cyclic amine, wherein said cyclic amine is optionally condensed with a 5- or 6-membered unsaturated heterocycle, that is optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group, 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 1-6  alkoxy-carbonyl group; 
 
 R 7  is
 a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, and 
 (c) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 
 
 R 8  is
 (1) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group optionally substituted by C 6-10  aryl group(s), 
 (c) a C 3-6  cycloalkyl group optionally substituted by C 1-6  alkoxy group(s), 
 (d) a C 6-10  aryl group, 
 (e) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by oxo group(s), 
 (f) a 5- to 8-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from 
  (i) a hydroxy group, 
  (ii) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy group, and 
  (iv) an oxo group, 
 (g) a C 3-6  cycloalkyloxy group, 
 (h) a C 6-10  aryloxy group, 
 (i) a 5- or 6-membered unsaturated heterocyclyloxy group, 
 (j) a 5- or 6-membered saturated heterocyclyloxy group, and 
 (k) an amino group optionally mono- or di-substituted by substituents selected from 
  (i) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a carboxy group and a carboxy-C 1-6  alkoxy group, 
  (ii) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy-carbonyl group optionally substituted by C 6-10  aryl group(s), and 
  (iv) a C 3-6  cycloalkyl-carbonyl group optionally substituted by C 1-6  alkoxy group(s), 
 
 
 (2) a C 1-6  alkoxy group optionally substituted by C 6-10 aryl group(s), 
 (3) a C 3-6  cycloalkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, 
 
 (4) a C 6-10  aryl group optionally substituted by C 1-6  alkyl group(s) optionally substituted by 1 to 3 halogen atoms, 
 (5) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s) optionally substituted by C 6-10 aryl group(s), 
 (6) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), 
 (7) a 5- or 6-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a C 1-6  alkyl group, 
 (b) a C 1-6  alkyl-carbonyl group, and 
 (c) an oxo group, 
 
 (8) a C 3-6  cycloalkyloxy group, or 
 (9) a C 6-10  aryl-carbonyl group, or 
 
         R 7  and R 8  form, together with the nitrogen atom and carbon atom they are bonded to, a 5- or 6-membered cyclic amine substituted by an oxo group and optionally further substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group optionally substituted by hydroxy group(s), 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 3-6  cycloalkyl group; and 
 
         R 10  is an amino-protecting group selected from the group consisting of a tert-butoxycarbonyl group, an ethoxycarbonyl group, a trityl group, a tetrahydropyranyl group, a methoxymethyl group, a 2-(trimethylsilyl)ethoxymethyl group, and a p-toluenesulfonyl group. 
       
     
     
         30 . A compound of formula [3] 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is
 (1) a hydrogen atom, 
 (2) a hydroxy group, or 
 (3) a C 1-6  alkoxy group optionally substituted by C 6-10  aryl group(s); 
 
         R 2  and R 3  are the same or different and each is
 a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group; 
 
 
         R 4  is a group selected from 
       
       
         
           
           
               
               
           
         
          which is bonded to the 5-position or the 6-position of the indole ring,
 wherein 
 R 5  is
 (1) a hydrogen atom, or 
 (2) a C 1-6  alkyl group, and 
 
 R 6  is
 (1) a hydrogen atom, 
 (2) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, 
 (c) a carboxy group, 
 (d) a C 1-6  alkoxy-carbonyl group, 
 (e) a C 6-10  aryl group, 
 (f) a C 6-10  aryloxy group, 
 (g) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 (h) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), and 
 (i) a 5- or 6-membered saturated heterocyclic group, 
 
 (3) a C 1-6  alkoxy group, 
 (4) a C 6-10  aryl group, or 
 (5) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, or 
 
 
 R 5  and R 6  form, together with the nitrogen atom they are bonded to, a 5- or 6-membered cyclic amine, wherein said cyclic amine is optionally condensed with a 5- or 6-membered unsaturated heterocycle, that is optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group, 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 1-6  alkoxy-carbonyl group; 
 
 R 7  is
 a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group, and 
 (c) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s), 
 
 
 R 8  is
 (1) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkoxy group optionally substituted by C 6-10 aryl group(s), 
 (c) a C 3-6  cycloalkyl group optionally substituted by C 1-6  alkoxy group(s), 
 (d) a C 6-10  aryl group, 
 (e) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by oxo group(s), 
 (f) a 5- to 8-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from 
  (i) a hydroxy group, 
  (ii) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy group, and 
  (iv) an oxo group, 
 (g) a C 3-6  cycloalkyloxy group, 
 (h) a C 6-10  aryloxy group, 
 (i) a 5- or 6-membered unsaturated heterocyclyloxy group, 
 (j) a 5- or 6-membered saturated heterocyclyloxy group, and 
 (k) an amino group optionally mono- or di-substituted by substituents selected from 
  (i) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a carboxy group and a carboxy-C 1-6  alkoxy group, 
  (ii) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C 1-6  alkoxy group, 
  (iii) a C 1-6  alkoxy-carbonyl group optionally substituted by C 6-10  aryl group(s), and 
  (iv) a C 3-6  cycloalkyl-carbonyl group optionally substituted by C 1-6  alkoxy group(s), 
 
 (2) a C 1-6  alkoxy group optionally substituted by C 6-10  aryl group(s), 
 (3) a C 3-6  cycloalkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, and 
 (b) a C 1-6  alkoxy group, 
 
 (4) a C 6-10  aryl group optionally substituted by C 1-6  alkyl group(s) optionally substituted by 1 to 3 halogen atoms, 
 (5) an amino group optionally mono- or di-substituted by C 1-6  alkyl group(s) optionally substituted by C 6-10  aryl group(s), 
 (6) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by C 1-6  alkyl group(s), 
 (7) a 5- or 6-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a C 1-6  alkyl group, 
 (b) a C 1-6  alkyl-carbonyl group, and 
 (c) an oxo group, 
 
 (8) a C 3-6  cycloalkyloxy group, or 
 (9) a C 6-10  aryl-carbonyl group, or 
 
 R 7  and R 8  form, together with the nitrogen atom and carbon atom they are bonded to, a 5- or 6-membered cyclic amine substituted by an oxo group and optionally further substituted by 1 to 3 substituents selected from
 (a) a hydroxy group, 
 (b) a C 1-6  alkyl group optionally substituted by hydroxy group(s), 
 (c) a C 1-6  alkoxy group, and 
 (d) a C 3-6  cycloalkyl group; and 
 
 
         R 9  and R 10  are the same or different and each is an amino-protecting group selected from the group consisting of a tert-butoxycarbonyl group, an ethoxycarbonyl group, a trityl group, a tetrahydropyranyl group, a methoxymethyl group, a 2-(trimethylsilyl)ethoxymethyl group, and a p-toluenesulfonyl group.

Join the waitlist — get patent alerts

Track US2018362506A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.